Michael Bison is a partner in Goodwin’s nationally and internationally recognized Technology and Life Sciences practice group and a member of its Life Sciences and Capital Markets practices. He represents privately held and publicly traded companies with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, diagnostics and healthcare information technology. Mr. Bison also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments, exits and secondary stock sale transactions, as well as underwriters focused on the life sciences industry in connection with capital market and M&A transactions.

Mr. Bison typically serves as outside general counsel to his clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including company formation and founder issues, venture capital and growth equity financings, public offerings, M&A, strategic collaborations, commercial transactions, corporate governance and general corporate matters. He is regularly recognized by his clients for his extensive industry knowledge and for providing practical, result-oriented legal advice.

Mr. Bison has advised numerous international companies with respect to their U.S. listings, capital markets transactions, strategic collaborations and M&A transactions, as well as with respect to the establishment of U.S. subsidiaries and various operational matters with respect to these subsidiaries.

Mr. Bison’s work has been recognized by several industry publications, including the Best Lawyers in America, LMG Life Sciences, The Legal 500, Law & Politics magazine, and Boston magazine.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Representative Matters

REFERENZMANDATE

代表事项

IPOs and Follow-On Transactions
  • Orchard Therapeutics in its $225.5 million initial public offering and initial U.S. listing and its $128.3 million follow-on offering
  • Allena Pharmaceuticals in its $75 million initial public offering and $9.8 million registered direct offering
  • Argenx in its $114.7 million initial public offering and multiple follow-on offerings
  • Chiasma in its $101.8 million initial public offering and its $55 million follow-on offering
  • Celyad SA in its $100.1 million initial public offering and U.S. listing and multiple follow-on offerings
  • Galapagos NV in its $275 million initial public offering and initial U.S. listing and multiple follow-on offerings
  • DBV Technologies S.A. in its $133.1 million global offering and initial U.S. listing
  • Sage Therapeutics in its $103.5 million initial public offering and $138 million follow-on offering
  • bluebird bio in its $116.1 million initial public offering and multiple follow-on offerings
  • Amarin Corporation in multiple follow-on offerings
  • Amarin Corporation in its $150 million 144A note offering and $118.7 million privately negotiated note exchange
  •  Underwriters in Intrexon Corporation’s $184 million initial public offeringLeerink Partners in a $57.5 million follow-on offering for Ovascience
  • Aegerion Pharmaceuticals in its $54.6 million initial public offering
  • LeMaitre Vascular in its $38.5 million initial public offering
  • athenahealth in its $90 million initial public offering
Private Company Financing Transactions
  • Synspira Therapeutics on its $3 million Series A financing
  • Wellframe Inc. on its $17 million Series C financing
  • OM1 in its $15 million Series A and $21 million Series B financing
  • 2020 Inc. on its Series A, Series A-1 and Series B financings
  • Lumicell Inc. on its $28.7 million Series C financing and $27.2 million Series D financing
  • Exosome Diagnostics in its $30 million Series C financing
  • Docent Health in its $17 million Series A financing
  • GliaCure in its $6 million Series B financing
  • Mitralign in its $40 million Series E financing
  • Exosome Diagnostics in its $27 million Series B financing
  • HealthWyse in multiple rounds of private financing (undisclosed)
  • meQuilibrium in multiple rounds of private financing (undisclosed)
  • bluebird bio in its $35 million Series C and $60 million Series D financing transactions
  • FRX Polymers in its $26.7 Series B, $20 million Series C and $22 million Series D financing transactions
  • Zeo in its $8.3 million Series C and $12.3 million Series D financing transactions
M&A Transactions
  • Mitralign, Inc. in its sale to Edwards Lifesciences Corporation (NYSE: EW)
  • Juniper Pharmaceuticals (Nasdaq: JNP) in its sale to Catalent (NYSE: CTLT)
  • Exosome Diagnostics in its sale to Bio-Techne (NASDAQ: TECH)
  • HealthWyse in its sale to Casamba / ABRY Partners
  • bluebird bio (NASDAQ: BLUE) in its acquisition of Precision Genome Engineering
  • VitalMed in its sale to PPC Industries
  • TrialNetworks in its sale to DrugDev
  • Outcome Sciences in its sale to Quintiles Transnational (NASDAQ: Q)
  • Mpathy Medical in its sale to Coloplast (COLOB.CO)
  • Progentix Orthobiology in its sale to NuVasive (NASDAQ: NUVA)
  • Ascension Ventures in the acquisition of MedVentive by McKesson Corporation (NYSE: MCK)
  • Ascension Ventures in the acquisition of BodyMedia by Jawbone
  • Forbion Capital Partners in the acquisition of BioVex by Amgen (NASDAQ: AMGN)
Venture Capital Transactions
  • Frazier Healthcare Partners, New Leaf Ventures, Soffinova Ventures and Canaan Partners in connection with a venture investment in Iterum Therapeutics
  • Bessemer Venture Partners and others in multiple rounds of venture investment in Acceleron Pharma, Fractyl Laboratories, Ovascience, Verastem, Proteon Therapeutics, Sirtris Pharmaceuticals and others
  • Third Rock Ventures and others in multiple round of venture investment in Allena Pharmaceuticals and Alcresta
  • Abingworth Life Sciences and others in connection with venture investments in Chiasma and Avedro
  • Ascension Ventures and others in multiple rounds of venture investment in BodyMedia, Inc., Ocular Therapeutix, Vascular Pathways, Cheetah Medical and others
  • Lightstone Ventures and others in connection with a venture investment in Catabasis
  • Forbion Capital Partners and others in multiple rounds of venture investment in Circulite, Mitralign, Pathway Medical, Promedior and others
  • Other leading VC firms, including Flagship Ventures, General Catalyst Partners, Advanced Technology Ventures and MVM Life Sciences, in connection with their portfolio investments and related matters
Professional Activities

Mr. Bison has served on the board of directors of MassMEDIC and is a member, through the firm, of the Biotechnology Industry Organization (BIO) and Massachusetts Biotechnology Council (MBC). He is also a member of the American and Boston Bar Associations.

Professional Experience

Prior to joining Goodwin, Mr. Bison was a member of the Business Practice Group at Testa, Hurwitz & Thibeault, LLP in Boston. Prior to beginning his legal career, he was a business and information systems consultant at Andersen Consulting, LLP (now Accenture Ltd.).

Recognition

Mr. Bison has been recognized in the Best Lawyers in America for his work in the areas of Biotechnology and Life Sciences, Mergers and Acquisitions Law and Venture Capital Law. He is also recognized for being an outstanding practitioner in the United States as one of the LMG Life Sciences’ Life Sciences Stars in the areas of Financial & Corporate and Mergers & Acquisitions. He has been selected for inclusion in The Legal 500 and recognized as a Massachusetts Super Lawyer “Rising Star” by Law & Politics and Boston magazines.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 1998
Northeastern University School of Law
B.A., 1993
College of the Holy Cross

(cum laude)

Admissions

Bar

Massachusetts
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师